Allergy testing and treatment company Nectar Life Sciences announced the opening of the Nectar Allergy Center in New York, its first brick-and-mortar clinic, to expand its virtual care platform to a hybrid model.
Nectar, which launched earlier this year, offers at-home testing kits. Individuals can self-test for indoor or outdoor allergies and send their samples to Nectar for results.
In December, Nectar scored $16.5 million in Series A funding, months after securing $8 million in seed funding. The Series A round brought the company’s total raise to more than $24 million.
Testers can then connect with licensed physicians through Nectar’s platform and receive a patent-pending formulated treatment plan, which includes sublingual drops. The drops target a specific allergy and train the immune system to tolerate the allergen over time.
The company announced it is increasing its offerings to include more allergic conditions, such as food allergies, eczema and asthma, and is adding additional allergists to its leadership team, Mobi Health News reports. Read more.
